Literature DB >> 7861027

Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells.

S Fais1, M R Capobianchi, M Silvestri, F Mercuri, F Pallone, F Dianzani.   

Abstract

The in vivo interferon (IFN) activation in Crohn's disease was evaluated by measuring the relative amounts of IFN-alpha and -gamma mRNA in freshly isolated human lamina propria mononuclear cells (LPMC) from patients with Crohn's disease and controls. Both IFN-gamma and IFN-alpha mRNA, as estimated by dot blot analysis, were increased in Crohn's disease (LPMC), although the relative amounts of IFN mRNA appeared to differ among patients. Appreciable amounts of IFN-gamma mRNA were found in Crohn's disease peripheral blood mononuclear cells (PBMC) extracts, whereas the same cells were negative for IFN-alpha mRNA. Only minute amounts of IFN-gamma RNA were found sporadically in control LPMC while no IFN-alpha was detected. Control PBMC were shown to be virtually negative for both IFN-alpha and IFN-gamma mRNA. These data suggest that IFN induction in the normal human gut is a well-controlled function and that in Crohn's disease tissues, both IFN-gamma and IFN-alpha production are dysregulated. The increased IFN activity may represent a major feature in the induction and perpetuation of the chronic inflammatory process in Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861027     DOI: 10.1089/jir.1994.14.235

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  15 in total

1.  Experimental colitis is associated with transcriptional inhibition of Na+/Ca2+ exchanger isoform 1 (NCX1) expression by interferon γ in the renal distal convoluted tubules.

Authors:  Vijayababu M Radhakrishnan; Pawel Kojs; Rajalakshmy Ramalingam; Monica T Midura-Kiela; Peter Angeli; Pawel R Kiela; Fayez K Ghishan
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

Review 2.  Intestinal barrier function: molecular regulation and disease pathogenesis.

Authors:  Katherine R Groschwitz; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2009-07       Impact factor: 10.793

3.  Interleukin 12 and Th1 responses in inflammatory bowel disease.

Authors:  F Pallone; G Monteleone
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

4.  Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice.

Authors:  R Ito; M Shin-Ya; T Kishida; A Urano; R Takada; J Sakagami; J Imanishi; M Kita; Y Ueda; Y Iwakura; K Kataoka; T Okanoue; O Mazda
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 5.  Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.

Authors:  Clara Abraham; Parambir S Dulai; Séverine Vermeire; William J Sandborn
Journal:  Gastroenterology       Date:  2016-10-22       Impact factor: 22.682

6.  Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease.

Authors:  D Berrebi; M Besnard; G Fromont-Hankard; R Paris; J F Mougenot; P De Lagausie; D Emilie; J P Cezard; J Navarro; M Peuchmaur
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

7.  Interferon-gamma (IFN-gamma) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC).

Authors:  G Monteleone; T Parrello; I Monteleone; S Tammaro; F Luzza; F Pallone
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

Review 8.  Intestinal epithelial CD98: an oligomeric and multifunctional protein.

Authors:  Yutao Yan; Sona Vasudevan; Hang Thi Thu Nguyen; Didier Merlin
Journal:  Biochim Biophys Acta       Date:  2008-06-24

9.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

10.  Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines.

Authors:  S Fais; F Pallone
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.